Anti-Fibrinolytic: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
* Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding. | * Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding. | ||
'''INDICATIONS''' | '''INDICATIONS''' | ||
* [[Shock|Severe Hemorrhagic Shock]]. | * [[Hemorrhagic Shock|Severe Hemorrhagic Shock]]. | ||
'''CONTRAINDICATIONS''' | '''CONTRAINDICATIONS''' | ||
* Isolated head injury | * Isolated head injury | ||
Revision as of 15:55, 30 October 2018
Section 8 - MEDICATION GUIDELINES
8.19 ANTI-FIBRINOLYTICS
Tranexamic Acid (TXA)
DESCRIPTION
- Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding.
INDICATIONS
CONTRAINDICATIONS
- Isolated head injury
- Known hypersensitivity
- Age less than 16 years old
- Known pregnancy
PRECAUTIONS
- Rapid injection can cause hypotension
DOSAGE
- 1000 mg of TXA mixed in 100 ml or 250 ml of normal saline infused via IO or IV over 10 minutes. Should be administered via a rate limiting device such as a Dial-A-Flo. A Buretrol is not a rate limiting device.